ADVANCES IN NEUROBLASTOMA RESEARCH 4


Editors

Audrey E. Evans
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

June L. Biedler
Memorial Sloan-Kettering Cancer Center
New York, New York

Garrett M. Brodeur
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Giulio J. D'Angio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Akira Nakagawara
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

WILEY-LISS

A JOHN WILEY & SONS, INC., PUBLICATION
NEW YORK • CHICHESTER • BRISBANE • TORONTO • SINGAPORE
Contents

Contributors ................................................................. xiii
Preface
Garrett M. Brodeur, Giulio J. D’Angio, and Audrey E. Evans .................. xxv

GENETICS I
Characterization of the Region of Consistent Deletion Within 1p36 in Neuroblastomas
Peter S. White, Minoru Fujimori, Helen N. Marshall, Bruce A. Kaufman, and Garrett M. Brodeur ........................................... 3

Prospective Evaluation of N-myc Amplification and Deletion of the Short Arm of Chromosome 1 in Neuroblastoma Tumours: A Single Institution Study
Jean Michon, Olivier Delattre, Jean Michel Zucker, Martine Peter, Pascale Delonlay, Sylvia Luciani, Véronique Mosseri, Philippe Vielh, Sylvia Neuenschwander, and Gilles Thomas ............................... 11

Loss of the Putative Tumor Suppressor Gene Locus 1p36 as Investigated by a PCR Assay and N-myc Amplification in 48 Neuroblastomas: Results of the German Neuroblastoma Study Group Holger Christiansen, Olivier Delattre, Stephan Fuchs, Marco Theobald, Nina M. Christiansen, Frank Berthold, and Fritz Lampert ......................................................... 19

N-myc Gene Amplification in Neuroblastoma Determined by the Polymerase Chain Reaction
Murray D. Norris, Michelle Haber, Jayne Gilbert, Maria Kavallaris, Glenn M. Marshall, and Bernard W. Stewart .................................................... 27

Chromosome 1p Allelic Loss in Neuroblastoma: Prognosis, Genomic Imprinting, and 1;17 Translocations
Huib Caron, Peter van Sluis, Nadine van Roy, Loes Bekx, Patricia Maes, Ruth Pereira do Tanque, Rosalyn Slater, Jan de Kraker, Frank Speleman, P.A. Voute, Andries Westerveld, and Rogier Versteeg ............... 35

Preferential Amplification of the Paternal Allele in Neuroblastomas With N-myc Amplification
Judy M. Cheng, Jill L. Hiemstra, Sandra S. Schneider, Bruce A. Kaufman, Anna Naumova, Nai-Kong V. Cheung, Susan L. Cohn, Lisa Diller, Carmen Sapienza, and Garrett M. Brodeur ..................................................... 43
Contents

High-Resolution Mapping of the N-myc Amplicon Core Domain in Neuroblastomas
Jill L. Hiemstra, Sandra S. Schneider, and Garrett M. Brodeur .......................... 51

The N-myc Oncoprotein Is a Transcriptional Activator and Associates With Max and RBI Proteins
Achim Wenzel, Celina Czepulch, Jörg Schürmann, and Manfred Schwab ................ 59

Discussion: Genetics I .............................................................. 67

GENETICS II

Constructing a Physical Map Around a Constitutional t(1;13)(q22;q12) Breakpoint in a Patient With a Ganglioneuroblastoma
Antony J. Michalski and John K. Cowell .............................................. 79

Flow Cytometric DNA Analysis of Neuroblastoma: Clinical Significance of DNA Tetraploidy
Masafumi Naito, Makoto Iwafuchi, and Masayuki Hirota ................................. 87

Antisense Inhibition of CHI100 c-myc Expression Results in Reduced In Vitro Growth Kinetics and Loss of In Vivo Tumorigenesis
Angelo Rosolen, Jeffrey Toretsky, and Len Neckers ..................................... 95

Retinoic Acid and Forskolin Activate the Human MDRI Gene Promoter in Differentiated Neuroblasts
Eric Ferrandis and Jean Bénard ............................................................. 103

Prognostic Value of MDRI Gene Expression in Neuroblastoma: Results of a Multivariate Analysis

The Expression and Modulation of Proteins Associated With Physiological Cell Death in Neuroblastoma Cells
Naohiko Ikegaki, Makoto Kastamata, and Yoshihide Tsujimoto ....................... 117

Role of Tissue Transglutaminase in Neuroblastoma Cells Undergoing Apoptosis
Mauro Piacentini and Gerry Melino ......................................................... 123

Discussion: Genetics II ................................................................. 131

DIFFERENTIATION I

trn mRNA and Low Affinity Nerve Growth Factor Receptor mRNA Expression and Triploid DNA Content in Favorable Neuroblastoma Tumors
Per Kogner, Gisela Barbany, Olle Björk, Manuel A. Castello, Alberto Donfrancesco, Ursula G. Falkner, Fredrick Hedborg, Hara Kouvidou, Håkan Persson, Giuseppe Raschella, and Carlo Dominici ............................. 137
Expression of Nerve Growth Factor Receptor mRNAs and Clinical Response to Retinoic Acid in Neuroblastoma
Per Kogner, Gisela Barbany, Håkan Persson, Stefan Söderhäll, Lars Åhström, and Olle Björk ........................................ 147

Clinical Significance of Expression of Neurotrophic Factors and Their Receptors in Neuroblastoma
Akira Nakagawara, Miwako Arima-Nakagawara, Christopher G. Azar, Nancy J. Scavarda, and Garrett M. Brodeur ........................................................................ 155

High Affinity Nerve Growth Factor Receptor Expression (gp140 K), N-myc Amplification, Histopathology, and Survival in Neuroblastoma
Munenori Miyake, Takashi Suzuki, Hiroyuki Shimada, Daniel Stram, and Robert C. Seeger .................................................... 163

Expression and Function of the Nerve Growth Factor Receptor (TRK-A) in Human Neuroblastoma Cell Lines
Christopher G. Azar, Nancy J. Scavarda, Akira Nakagawara, and Garrett M. Brodeur ................................................................. 169

NGF Induces Terminal Differentiation in trkA Expressing Neuroblastoma Cells In Vitro and In Vivo
Hiroshi Matsushima and Emil Bogenmann .................................................. 177

Retinoic Acid-Induced Differentiation Is Mediated by TRK-B Receptors
Enrico Lucarelli, David Kaplan, Kazue Matsumoto, Sharon Sickafuse, and Carol J. Thiele ................................................................. 185

Discussion: Differentiation I ................................................................. 199

DIFFERENTIATION II
Expression of Retinoic Acid Receptors α, β, and γ in Human Neuroblastoma Cell Lines
Chun Li, Peggy A. Einhorn, and C. Patrick Reynolds ........................................ 221

Retinoic Acid-Induced Expression of Homeobox Genes in Human Neuroblastoma Cells
Chitra F. Manohar, Helen R. Salwen, M.R. Furtado, and Susan L. Cohn ................................................................. 229

Comparison of 13-cis Retinoic Acid to trans Retinoic Acid Using Human Neuroblastoma Cell Lines
C. Patrick Reynolds, Peter F. Schindler, Donna-Maria Jones, Jennifer L. Gentile, Robert T. Proffitt, and Peggy A. Einhorn ................................................................. 237

Expression of Retinoic Acid-Responsive Genes in Primary Neuroblastomas
Michelle Haber, Janice Madafsiglio, Sharon B. Bordow, Jayne Gilbert, Belamy Cheung, Glenn M. Marshall, and Murray D. Norris ........................................ 245

Differentiation-Inducing Agents Stably Convert Human Neuroblastoma I-Type Cells to Neuroblastic (N) or Nonneuronal (S) Neural Crest Cells
Robert A. Ross, Barbara A. Spengler, Wolfgang J. Reitig, and June L. Biedler .................. 253
x / Contents

Human Neuroblastoma Lines Respond Differently to Diverse Differentiation-Inducing Agents
Barbara A. Spengler, Carles Domènech, Michael Porubcin, and June L. Biedler ........................................... 261

Autocrine Regulation of Neuroblastoma Cell Growth and Differentiation by Vasoactive Intestinal Peptide
Jeffrey C. Pence, Billie-Jo M. Kerns, and Nicholas A. Shorter .................................................... 269

Ha-ras p21 in Neuroblastoma: A New Marker in Prediction of Patient Outcome
Takeo Tanaka ................................................................. 275

Discussion: Differentiation II ............................................. 281

BIOLOGY AND THERAPY

Myeloablate Chemoradiotherapy Versus Continued Chemotherapy for High Risk Neuroblastoma
Daniel O. Stram, Katherine K. Mathay, Maura O’Leary, C. Patrick Reynolds, and Robert C. Seeger ............... 287

Administration of High-Dose Recombinant Interleukin 2 After Autologous Bone Marrow Transplantation in Patients With Neuroblastoma: Toxicity, Efficacy, and Survival. A Lyon-Marseille-Curie-East of France Group Study

Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Neuroblastoma

Peripheral Stem Cell Transplantation in Neuroblastoma Stage 4 With the Use of 1³¹I-MIBG
Thomas Klingebiel, Rupert Handretinger, Michael Herter, Peter Lang, Roland Dopfer, Hans Scheet-Walter, and Dietrich Niethammer ................................................................. 309

3F8 Monoclonal Antibody Treatment of Patients With Stage IV Neuroblastoma: A Phase II Study
Nai-Kong V. Cheung, Brian H. Kushner, Samuel J. Yeh, and Steven M. Larson .......................... 319

Proof of the Reactive Nature of the Schwann Cell in Neuroblastoma and Its Clinical Implications
Inge M. Ambros, Andrea Zeilner, Cornelia Stock, Gabriele Amann, Helmut Gadner, and Peter F. Ambros ................................. 331

Discussion: Biology and Therapy ........................................... 339
BIOLOGY AND SCREENING

Synthesis of Carrier-Free $^{131}$I-Meta-iodobenzylguanidine by Novel Routes to Enhance Therapeutic Efficiency in Neuroblastoma
Mark N. Gaze, Robert J. Mairs, Ganesan Vaidyanathan, and Michael R. Zalutsky ........................................ 347

Somatostatin Receptor Scintigraphy (SRS): A New Diagnostic Tool in Neuroblastoma (NB)?
Ulrich Dörr, Marie-Luise Sautter-Bihl, Freimut H. Schilling, Ewa Koscielniak, Jörn Treuner, and Heiner Bihl ........................................ 355

Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment

Analysis of 598 Cases of Neuroblastoma (NB) Detected by Screening and Changes in the Age Distribution and Incidence of NB Patients After Mass Screening in Infants in Japan
T. Sawada, T. Shikata, T. Matsumura, H. Kawakatsu, T. Sugimoto, and Members of the NB Screening Study Group ........................................ 371

Screening for Neuroblastoma (NB) in North America: The Quebec Project

Effects of Mass Screening for Neuroblastoma and the Presumptive Natural History of This Tumor
Takeo Takeda, Masako Shimada, Susumu Iizuka, and Nobuo Takasugi .......... 383

Discussion: Biology and Screening ........................................ 389

Abstracts From Poster Sessions ........................................ 397

Index ........................................ 449
Contributors

Gabriele Amann, Institute of Clinical Pathology, University of Vienna, A-1090 Vienna, Austria [331]
Inge M. Ambros, Children’s Cancer Research Institute, St. Anna Kinderspital, A-1090 Vienna, Austria [331]
Peter F. Ambros, Children’s Cancer Research Institute, St. Anna Kinderspital, A-1090 Vienna, Austria [331]
Lars Åhström, Department of Pediatrics, Karolinska Hospital, S-171 76 Stockholm, Sweden [147]
Miwako Arima-Nakagawara, Department of Pediatric Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104 [155]
James B. Atkinson, Department of Pediatrics, Children’s Hospital of Los Angeles, Los Angeles, CA 90027 [301]
Christopher G. Azar, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110 [155, 169]
Gisela Barbany, Department of Physiological Chemistry, Karolinska Institute, S-171 76 Stockholm, Sweden [137, 147]
Loes Bekx, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Jean Bénard, Laboratory of Molecular and Clinical Pharmacology, Institut Gustave Roussy, 94800 Villejuif, France [103, 111]
Jean-Louis Bernard, Département de Pédiatrie Oncologique, Hôpital de la Timone, 13005 Marseille, France [293]
Mark L. Bernstein, Montreal Children’s Hospital, Montreal, Quebec H3H 1P3, Canada [377]
Frank Berthold, Universitäts-Kinderklinik, D-5000 Köln, Germany [19, 363]
June L. Biedler, Laboratory of Cellular and Biochemical Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 1121 [253, 261]
Heiner Bihl, Department of Nuclear Medicine, Katharinenhospital, D-70174 Stuttgart, Germany [355]

The numbers in brackets are the opening page numbers of the contributors’ articles.
Olle Björk, Department of Pediatrics, Karolinska Hospital, S-171 76 Stockholm, Sweden [137, 147]

Emil Bogenmann, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [177]

Sharon B. Bordow, Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, Randwick, Sydney, NSW 2031, Australia [245]

Eric Bouffet, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]

J. Bourhis, Laboratory of Molecular and Clinical Pharmacology, Institut Gustave Roussy, 94800 Villejuif, France [111]

Linda Brisson, Centre Hospitalier l'Université Laval, Ste-Foy, Quebec G1V 4G2, Canada [377]

Garrett M. Brodeur, Department of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104 [3, 43, 51, 155, 169, 363, 377]

Josse Brossard, Department of Pediatrics, CHUS, Sherbrooke, Quebec J1H 5N4, Canada [377]

Niels L.T. Carlsen, Department of Pediatric Surgery, GGK University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark [363]

Huib Caron, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]

Victoria Castel, Department of Pediatrics, Hospital Infantil La-Fe, 46009 Valencia, Spain [363]

Manuel A. Castello, Department of Pediatrics, University of Rome "La Sapienza", 00161 Rome, Italy [137]

Robert P. Castleberry, Department of Pediatrics, Children's Hospital of Birmingham/UAB, Birmingham, AL 35233 [363]

Judy M. Cheng, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110 [43]

Belamy Cheung, Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, Randwick, Sydney, NSW 2031, Australia [245]

Nai-Kong V. Cheung, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [43, 319]

Holger Christiansen, Universitäts-Kinderklinik, D-6300 Giessen, Germany [19]

Nina M. Christiansen, Universitäts-Kinderklinik, D-6300 Giessen, Germany [19]

Pierre Cochat, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]
Ursula G. Falkmer, Department of Pathology, Karolinska Hospital, S-171 76 Stockholm, Sweden [137]
Marie Favrot, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293, 363]
Eric Ferrandis, Laboratory of Molecular and Clinical Pharmacology, Institut Gustave Roussy, 94800 Villejuif, France [103, 111]
Daniel Floret, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]
Chris R. Franks, Medical Department, EuroCetus B.V., 1105 BJ Amsterdam, The Netherlands [293]
Didier Frappaz, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]
Wolf Hermann Fridman, Unité Biotherapie, Institut Curie, 75231 Paris Cedex 05, France [293]
Stephan Fuchs, Universitäts-Kinderklinik, D-6300 Giessen, Germany [19]
Minoru Fujimori, The Second Department of Surgery, Shinshu University School of Medicine, Matsumoto 390, Japan [3]
M.R. Furtado, Department of Pathology, Northwestern University, Chicago, IL 60611 [229]

Helmut Gadner, Children’s Cancer Research Institute, St. Anna Kinderspital, A-1090 Vienna, Austria [331]
Mark N. Gaze, Department of Radiation Oncology, University of Glasgow, Glasgow G61 1RD, United Kingdom [347]
Jennifer L. Gentile, Division of Hematology-Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA 90027 [237]
Jayne Gilbert, Children’s Leukaemia and Cancer Research Centre, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [27, 245]
Gerald Haase, Department of Pediatrics, Children’s Hospital of Denver, Denver, CO 80218 [301]
Michelle Haber, Children’s Leukaemia and Cancer Research Center, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [27, 245]
G. Denman Hammond, Children’s Cancer Group Operations Office, 440 East Huntington Drive, Suite 300, Arcadia, CA 91006 [301]
Rupert Handgretinger, Department of Pediatric Hematology/Oncology, Children’s Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]
Richard E. Harris, Bone Marrow Transplant Program, Children’s Hospital Medical Center, Cincinnati, OH 45229 [301]
O. Hartmann, Department of Pediatric Oncology, Institut Gustave Roussy, 94800 Villejuif, France [111]
Fredrick Hedborg, Department of Pediatrics, Uppsala University Hospital, S-751 85 Uppsala, Sweden [137, 363]
Michael Herter, Department of Pediatric Hematology/Oncology, Children's Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]
Jill L. Hiemstra, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110 [43, 51]
Masayuki Hirota, Department of Pediatric Surgery, Niigata University School of Medicine, Niigata City, Niigata 951, Japan [87]
Susumu Iizuka, Department of Pediatrics, Sapporo National Hospital, Sapporo City, Sapporo 003, Japan [383]
Naohiko Ikekaki, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 [117]
Makoto Iwafuchi, Department of Pediatric Surgery, Niigata University School of Medicine, Niigata City, Niigata 951, Japan [87]
Donna-Marla Jones, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [237]
Michio Kaneko, Department of Pediatric Surgery, University of Tsukuba, Tsukuba 305, Japan [363]
David Kaplan, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702 [185]
Makoto Kastumata, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 [117]
Bruce A. Kaufman, Department of Pediatrics/Neurosurgery, Washington University School of Medicine, St. Louis, MO 63110 [3, 43]
Maria Kavallaris, Children's Leukaemia and Cancer Research Centre, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [27]
H. Kawakatsu, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan [371]
John Kemshhead, Imperial Cancer Research Foundation, Frenchay Hospital, Bristol BS16 1LE, England [363]
Billie-Jo M. Kerns, Department of Surgery, Duke University Medical Center, Durham, NC 27710 [269]
Thomas Klingebiel, Department of Pediatric Hematology/Oncology, Children’s Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]
Per Kögner, Department of Pediatrics, Karolinska Hospital, S-171 76 Stockholm, Sweden [137, 147]
Ewa Koscielniak, Department of Oncology and Hematology, Olga Hospital, D-70176 Stuttgart, Germany [355]

Hara Kouvidou, Department of Pathology, Karolinska Hospital, S-171 76 Stockholm, Sweden [137]

Brian H. Kushner, Department of Pediatrics, Memorial Sloan-Kettering Cancer, New York, NY 10021 [319]

Fritz Lampert, Universitäts-Kinderklinik, D-6300 Giessen, Germany [19, 363]

Peter Lang, Department of Pediatric Hematology/Oncology, Children’s Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]

Florence Lanier, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]

Steven M. Larson, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [319]

Jean-Marie Leclerc, Ste-Justine Hospital, Montreal, Quebec H3T 1C5, Canada [377]

Richard E.J. Lee, Department of Radiology, Royal Victoria Infirmary, Newcastle NE 14 LP, England [363]

J. Lemerle, Department of Pediatric Oncology, Institut Gustave Roussy, 94800 Villejuif, France [111]

Bernard Lemieux, Department of Pediatrics, CHUS, Sherbrooke, Quebec J1H 5N4, Canada [377]

Chun Li, Division of Hematology-Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA 90027 [221]

A. Thomas Look, Department of Experimental Oncology, St. Jude Children’s Research Hospital, Memphis, TN 39105 [363, 377]

Enrico Lucarelli, National Cancer Institute, NIH, Bethesda, MD 20892 [185]

Sylvia Luciani, Unité de Biostatistiques, Institut Curie, 75231 Paris Cedex 05, France [11]

Janice Madafiglio, Children’s Leukaemia and Cancer Research Centre, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [245]

Patricia Maes, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]

Robert J. Mairs, Department of Radiation Oncology, University of Glasgow, Glasgow G61 1BD, United Kingdom [347]

Chitra F. Manohar, Department of Pediatrics, Northwestern University, Chicago, IL 60611 [229]

Glenn M. Marshall, Children’s Leukaemia and Cancer Research Centre, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [27, 245]
Helen N. Marshall, Department of Pediatrics/Surgery, Washington University School of Medicine, St. Louis, MO 63110 [3]
Claire Mathiot, Unité Biotherapie, Institut Curie, 75231 Paris Cedex 05, France [293]
Kazue Matsumoto, National Cancer Institute, NIH, Bethesda, MD 20892 [185]
T. Matsumura, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan [371]
Hiroshi Matsushima, Department of Pediatrics, Jikei University School of Medicine, Tokyo 105, Japan [177]
Katherine K. Matthyay, Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 [287, 301]
Gerry Melino, Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata", 00173 Rome, Italy [123]
Antony J. Michalski, Department of Haematology and Oncology, Institute of Child Health, London WC1N 1EH, England [79]
Jean Michon, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [11, 293]
Munenori Miyake, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [163]
Véronique Mosseri, Unité de Biostatistiques, Institut Curie, 75231 Paris Cedex 05, France [11]
Masaumi Naito, Department of Pediatric Surgery, Niigata University School of Medicine, Niigata City, Niigata 951, Japan [87]
Akira Nakagawara, Department of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104 [155, 169]
Anna Naumova, Department of Developmental Genetics, Ludwig Institute for Cancer Research, La Jolla, CA 92039 [43]
Len Neckers, National Cancer Institute, NIH, Bethesda, MD 70892 [95]
Sylvie Négrier, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293]
Sylvia Neuenschwander, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [11]
Dietrich Niethammer, Department of Pediatric Oncology, Children's Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]
Murray D. Norris, Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, Randwick, Sydney, NSW 2031, Australia [27, 245]
Maura O'Leary, Department of Pediatric Hematology-Oncology, Minneapolis Children's Medical Center, Minneapolis, MN 55404 [287, 301]
Ralph Oskam, Medical Department, EuroCetus B.V., 1105 BJ Amsterdam, The Netherlands [293]

Hélène Pacquement, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [293]

Peter Palmer, Medical Department, EuroCetus B.V., 1105 BJ Amsterdam, The Netherlands [293]

Andrew D.J. Pearson, Department of Child Health, University of Newcastle Upon Tyne, Newcastle NE2 4HH, England [363]

Jeffrey C. Pence, Department of Surgery, Duke University Medical Center, Durham, NC 27710 [269]

Ruth Pereira do Tanque, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]

†Håkan Persson, Department of Physiological Chemistry, Karolinska Institute, S-171 76 Stockholm, Sweden [137, 147]

Martine Peter, Laboratoire de Génétique des Tumeurs, Institut Curie, 75231 Paris Cedex 05, France [11]

Thierry Philip, Département de Pédiatrie Oncologique, Centre Léon Bérard, 69373 Lyon Cedex 02, France [293, 363]

Mauro Piacentini, Department of Biology, University of Rome “Tor Vergata”, 00173 Rome, Italy [123]

Michael Porubcin, Department of Cellular and Biochemical Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [261]

Jon Pritchard, Department of Hematology-Oncology, The Hospitals for Sick Children, London WC1N 3JH, England [363]

Robert T. Proffitt, Division of Hematology-Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA 90027 [237]

Erica Quintana, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [293]

Norma K. Ramsay, Department of Pediatrics, University of Minnesota Medical Center, Minneapolis, MN 55455 [301]

Giuseppe Raschella, Division of Molecular Biology, ENNEA, Casaccia, Rome, Italy [137]

Wolfgang J. Retting, Department of Human Cancer Immunogenetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [253]

C. Patrick Reynolds, Division of Hematology-Oncology, Children’s Hospital of Los Angeles, Los Angeles, CA 90027 [221, 237, 287, 301]

G. Riou, Department of Pediatric Oncology, Institut Gustave Roussy, 94800 Villejuif, France [111]

Borghild Roald, Institute of Pathology, University of Oslo Rikshospitalet, N-0027 Oslo, Norway [363]

†Deceased.
Leslie L. Robison, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455 [377]
Angelo Rosolen, Department of Pediatrics, University of Padova, 35128 Padova, Italy [95]
Robert A. Ross, Department of Biological Sciences, Fordham University, Bronx, NY 10458 [253]
Helen R. Salwen, Department of Pediatrics, Northwestern University, Chicago, IL 60611 [229]
Carmen Sapienza, Department of Developmental Genetics, Ludwig Institute for Cancer Research, La Jolla, CA 92039 [43]
Marie-Luise Sautter-Bihl, Department of Radiooncology and Nuclear Medicine, Klinikum Karlsruhe, D-76133 Karlsruhe, Germany [355]
Tadashi Sawada, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kamikyo-ku, Kyoto 602, Japan [363, 371]
Nancy J. Scavarda, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110 [155, 169]
Hans Scheel-Walter, Department of Pediatric Oncology, Children's Hospital, Eberhard Karls University, D-72070 Tübingen, Germany [309]
Freimut H. Schilling, Department of Oncology and Hematology, Olga Hospital, D-70176 Stuttgart, Germany [355]

Peter F. Schindler, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [237]
Sandra S. Schneider, Joint Program in Neonatology, Harvard Medical School, Boston, MA 02115 [43, 51]
Jörg Schürmann, Department of Cytogenetics, German Cancer Research Center, D-69120 Heidelberg, Germany [59]
Manfred Schwab, Department of Cytogenetics, German Cancer Research Center, D-69120 Heidelberg, Germany [59]
Robert C. Seeger, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [163, 287, 301, 363]
Michael Selch, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90024 [301]
T. Shikata, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan [371]
Hirokazu Shimada, Department of Pathology, Children's Hospital of Los Angeles, Los Angeles, CA 90027 [163]
Masako Shimada, Clinical Research Institute, Sapporo National Hospital, Sapporo City, Sapporo 003, Japan [383]
Nicholas A. Shorter, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756 [269]
Jonathan J. Shuster, POG Statistical Office, Gainesville, FL 32608 [377]
Sharon Sickafuse, National Cancer Institute, NIH, Bethesda, MD 20892 [185]
Rosalyn Slater, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Stefan Söderhäll, Department of Pediatrics, Karolinska Hospital, S-171 76 Stockholm, Sweden [147]
Frank Speleman, Department of Medical Genetics, Ghent, Belgium [35]
Barbara A. Spengler, Department of Cellular and Biochemical Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [253, 261]
Bernard W. Stewart, Children’s Leukaemia and Cancer Research Centre, Prince of Wales Children’s Hospital, Randwick, Sydney, NSW 2031, Australia [27]
Cornelia Stock, Children’s Cancer Research Institute, St. Anna Kinderspital, A-1090 Vienna, Austria [331]
Daniel O. Stram, Children’s Cancer Group, 440 East Huntington Drive, Suite 300, Arcadia, CA 91006 [163, 287, 301]
T. Sugimoto, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan [371]
Takashi Suzuki, Department of Pediatrics, Nihon University School of Medicine, Tokyo 173, Japan [163]
Nobuo Takasugi, Health and Sanitary Bureau, Sapporo City, Sapporo 003, Japan [383]
Takeo Takeda, Clinical Research Institute, Sapporo National Hospital, Sapporo 003, Japan [383]
Takeo Tanaka, Department of Pediatrics, National Kure Hospital, Kure City, Hiroshima 737, Japan [275]
M.J. Terrier-Lacombe, Department of Pathology, Institut Gustave Roussy, 94800 Villejuif, France [111]
Marco Theobald, Universitäts-Kinderklinik, D-6300 Giessen, Germany [19]
Carol J. Thiele, National Cancer Institute, NIH, Bethesda, MD 20892 [185]
Gilles Thomas, Laboratoire de Génétique des Tumeurs, Institut Curie, Paris 75231 Cedex 05, France [11]
Jeffrey Toretsky, National Cancer Institute, NIH, Bethesda, MD 20892 [95]
Jörn Treuner, Department of Oncology and Hematology, Olga Hospital, D-70176 Stuttgart, Germany [355]
Yoshiaki Tsuchida, Department of Surgery, University of Tokyo, Tokyo 113, Japan [363]
Yoshiihide Tsujimoto, Department of Medical Genetics, Osaka University Medical School, Suita, Osaka 565, Japan [117]
Mendel Tuchman, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455 [377]
Ganesan Vaidyanathan, Department of Radiology, Duke University Medical Center, Durham, NC 27710 [347]
Nadine van Roy, Department of Medical Genetics, University Hospital, Ghent, Belgium [35]
Peter van Sluis, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Rogier Versteeg, Institute of Human Genetics, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Philippe Vieth, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [11]
Paul A. Voûte, Department of Paediatric Oncology and Haematology, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Sheila Weitzman, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada [377]
Achim Wenzel, Department of Cytogenetics, German Cancer Research Center, D-69120 Heidelberg, Germany [59]
Andries Westerveld, Institute of Human Genetics, Academic Medical Centre, University of Amsterdam, NL-1105 AZ Amsterdam, The Netherlands [35]
Peter S. White, Department of Pediatric Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA 19104 [3]
William G. Woods, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455 [377]
Samuel J. Yeh, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [319]
Michael R. Zalutsky, Department of Radiology, Duke University Medical Center, Durham, NC 27710 [347]
Andrea Zellner, Children’s Cancer Research Institute, St. Anna Kinderspital, A-1090 Vienna, Austria [331]
Jean Michel Zucker, Département de Pédiatrie Oncologique, Institut Curie, 75231 Paris Cedex 05, France [11]
Preface

The Children's Hospital of Philadelphia has hosted an international conference devoted to neuroblastoma research every three or four years since 1975. The first one, held in a small conference room, was attended mostly by pediatric oncologists, a few pathologists, and a sprinkling of geneticists. The most recent one, in 1993, was the sixth such conference. It was attended by over 200 people from all over the world, with a large proportion of molecular biologists and other basic scientists interested in this tantalizing neoplasm. The focus of the 1993 symposium, held over three days, was on laboratory studies as they relate to neuroblastoma. The first day was devoted to Genetics, the second to Differentiation, and the third to Therapy and Screening.

This volume contains the manuscripts of the verbal presentations and transcripts of the discussions, as well as the posters that were displayed.

At the 1990 conference, many of the papers in the genetics session dealt with \textit{N-myc} amplification and its relationship to aggressive behavior. It is increasingly apparent that this is only one of the changes that lead to aggressive disease; there are other equally aggressive tumors that lack obvious gene amplification. Many of the papers in the 1993 genetics session dealt with a possible suppressor gene in the region of 1p36, and its deletion in a subset of tumors. A study of tumor specimens from high-risk patients showed that \textit{N-myc} amplification and 1p loss of heterozygosity (LOH) were associated strongly with each other and with a bad outcome. Nevertheless, in half the patients, neither \textit{N-myc} amplification nor 1p LOH was detected. A similar study, which included patients with both good and bad prognoses, showed that only one out of 12 patients with low-stage disease had 1p LOH and none had \textit{N-myc} amplification. In contrast, one-third of the more advanced patients had 1p LOH, \textit{N-myc} amplification, or both. A new area of research involved expression of the \textit{MDRI} gene. \textit{MDRI} expression occurred with the same frequency in localized or metastatic disease, but was associated with an increased death rate if results were limited to stage IV tumors and those having had previous treatment. A second paper reported that increased \textit{MDRI} gene expression was associated with differentiation following retinoic acid treatment.

The session on differentiation included several papers on cell surface re-
ceptors. Many dealt with the presence of high affinity nerve growth factor receptor, or TRK, as it relates to prognosis and its response to retinoic acid treatment. Three papers showed that the presence of high TRK expression was associated with young age and low stage, and thus a significant survival advantage, and TRK may also play a role in mediating programmed cell death. Other papers showed that exposure to retinoic acid led to increased expression of TRK-A and TRK-B. Several papers dealt with the effects of retinoic acid on differentiation, and one compared the effects of 13-cis-retinoic acid to trans-retinoic acid on human neuroblastoma cell lines.

The third day of the symposium was devoted to more clinically related papers, including the results from hypertherapy with bone marrow and peripheral stem cell rescue, and the role of 131-I-Meta-iodobenzylguanidine (MIBG). There were two papers on the use of monoclonal antibody treatment with or without radio labeling. Lastly, there were four papers and much discussion on the role of mass screening in the detection of neuroblastoma at a young age and possibly at a more treatable stage. The debate in this area revolved around the issue of whether patients with aggressive neuroblastoma actually start with the more benign form, and if so, could treatment prevent its progression to aggressive disease. The contrary stance, held by some, is that screening simply detects patients with favorable disease who require little or no treatment anyhow. It was obvious from the Japanese experience that an increased number of patients is picked up by screening, approximately twice that previously detected by clinical methods alone.

It is apparent that the enigmas of neuroblastoma have attracted an increasing number of laboratory scientists since the first conference 18 years ago. The basic mechanisms of favorable and unfavorable disease are being described. Their understanding will have wide repercussions. At the clinical level, more targeted forms of treatment will help achieve the basic aim of pediatric oncology — cure with minimum complications. At the fundamental level, time, unraveling the mysteries of this unique tumor, will provide greater insights into the nature of the malignant process itself.

Garrett M. Brodeur
Giulio J. D'Angio
Audrey E. Evans